Home > Business Events
ITALIAN BIOTECH RESEARCH AND INNOVATION MEETS EUROPE
Bio-Europe, the most important European convention dedicated to the field of biotechnology, is celebrating its 20-year anniversary.
In two decades, the sector has grown exponentially and, with it, the event which will be held from 3 to 5 November at the fair in Frankfurt.
The event, which takes place every year in different cities in Germany and Austria, is the benchmark platform for European companies in the sector, and brings together decision-makers of the biotech sector and representatives of the financial world.
It is therefore a unique opportunity to witness the excellence of Italian biotech companies. In fact, the Ice Agency has selected 14 top biotech companies along with regional promotion agencies, making up the Italian group that will take part in the fair. Italian biotechnology is a dynamic and competitive industry at European level, despite often involving small and medium-sized enterprises.
The latest report by Ernst & Young showed how 422 biotechnological firms have been recorded in Italy with a turnover of 7.05 billion euros. Just like in other countries, in Italy, the health sector is driving the entire industry, both in terms of number of firms (57%) and turnover (6.6 billion). However, 88% of Italian biotech companies have fewer than 50 employees.
At the Italian pavilion, which is centrally located, you can assess the opportunities for collaboration and partnership with companies that represent the excellence of Italian biotech in terms of research, development and innovation. Of course, this will particularly focus on the pharmaceutical and health sector, but also others.
There will be companies which operate in the manufacture of equipment to control air contamination or laminar flow safety cabinets, as well as highly specialised entities in specific areas of research. This will provide a unique opportunity for exchange and growth, as well as to share skills and expertise.
Such meetings are in fact one of the fair’s main features, as demonstrated by the nearly 18 thousand one-to-one meetings recorded last year alone, and the 3,200 delegates representing more than 1,800 companies that have participated in the event. Andreas Busch, member of the Bayer HealthCare Executive Committee and Head of Global Drug Discovery of Bayer HealthCare emphasised the following point when presenting the event: “We appreciate Bio-Europe because we can meet face-to-face with a large number of companies, and this really maximises our partnership efforts”.
The event dedicated to biotechnology, together with pharmaceutical and biotech companies, will be attended by research centres, companies related to professional services, and specialised investors.